Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2024-04-23 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
内部控制审计报告
Regulatory Filings
2024-04-23 Chinese
独董提名人声明与承诺-程隆云
Board/Management Information Classification · 95% confidence The document is a formal statement and commitment regarding the nomination of an independent director candidate for the company's board. It includes detailed declarations about the nominee's qualifications, compliance with laws and regulations, and independence criteria. There is no financial data, earnings information, or report publication mentioned. The content focuses on board/management information, specifically the nomination of a board member. Therefore, the document fits the category of Board/Management Information (MANG). The document length is sufficient and contains substantive content related to management changes rather than a brief announcement or regulatory filing.
2024-04-23 Chinese
北京双鹭药业股份有限公司内幕信息知情人登记管理制度（2024.04）
Governance Information Classification · 95% confidence The document is titled '内幕信息知情人登记管理制度' which translates to 'Insider Information Insider Registration Management System'. It is a detailed internal policy document from Beijing SL Pharmaceutical Co., Ltd. regarding the management, registration, and confidentiality of insider information and insider persons. It includes definitions, scope, procedures for registration, confidentiality obligations, and attachments such as confidentiality agreements and insider trading prohibition notices. The document is regulatory and procedural in nature, focusing on compliance with securities laws and insider information management. It does not contain financial statements, earnings data, or investor presentations. It is not an announcement or a brief notice but a comprehensive internal governance document. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2024-04-23 Chinese
监事会决议公告
AGM Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Beijing Shuanglu Pharmaceutical Co., Ltd. It details the approval of various reports and proposals related to the 2023 annual report, financial statements, profit distribution plan, internal control self-assessment, and the 2024 first quarter report. The document is relatively short (3262 characters) and primarily announces the passing of these items by the Supervisory Board, indicating that these reports will be submitted to the 2023 Annual General Meeting for approval. It does not contain the full annual report or financial statements themselves but rather the Supervisory Board's review and approval of these documents. Therefore, this is not the Annual Report (10-K) itself but an announcement of resolutions related to the annual report and other reports. This fits best with the category of AGM Information (AGM-R), as it relates to materials and resolutions connected to the Annual General Meeting.
2024-04-23 Chinese
北京双鹭药业股份有限公司规范与关联方资金往来管理制度（2024.04）
Governance Information Classification · 95% confidence The document is a detailed internal policy titled '规范与关联方资金往来管理制度' (Regulations on Management of Funds Transactions with Related Parties) issued by Beijing SL Pharmaceutical Co., Ltd. It outlines rules and procedures for managing financial transactions between the company and its related parties, including controls, responsibilities, audit management, and penalties for violations. The content is regulatory and governance-focused, detailing internal controls and compliance with laws and stock exchange rules. It does not contain financial statements, earnings data, or shareholder meeting materials. It is not an announcement or a brief notice but a comprehensive governance document. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2024-04-23 Chinese
北京双鹭药业股份有限公司董事、监事及高级管理人员持有及买卖本公司股份的专项管理制度（2024.04）
Governance Information Classification · 95% confidence The document is a detailed internal policy regarding the holding and trading of company shares by directors, supervisors, and senior management of Beijing Shuanglu Pharmaceutical Co., Ltd. It outlines rules, restrictions, disclosure requirements, and penalties related to insider trading and share transactions by key company personnel. There is no indication that this is an announcement of a report, a financial statement, or a regulatory filing of financial results. Instead, it is a governance-related document focused on internal rules and compliance concerning shareholding and trading by insiders. Therefore, the document best fits the category of Governance Information (CGR). The document length (5797 characters) and content support this classification with high confidence.
2024-04-23 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.